13F-HR filed by Saturn V Capital Management LP
Saturn V Capital Management LP filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-15, with 21 holding rows worth $198,158,284.
- Accession
- 0001964437-25-000005
- Filer
- CIK 1964437
- Filed
- 2025-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2025
A holdings report, 21 entries on the cover page, a total value of $198,158,284 stated on the cover page (in dollars after the unit check, H1), rows summing to $198,158,284 with VALUE read as dollars as filed, 13F file number 028-22863. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 199,264 | $31,057,287 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 518,177 | $25,722,306 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 577,696 | $14,147,775 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 413,711 | $13,880,004 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 323,211 | $13,603,951 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 343,849 | $13,434,180 | dollars as filed | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 1,041,280 | $12,792,125 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 1,093,677 | $11,057,074 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 1,480,020 | $8,865,320 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 232,295 | $8,771,459 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 2,426,436 | $8,589,583 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 13,862 | $8,204,433 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 448,692 | $6,452,191 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 598,191 | $4,384,740 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 560,979 | $3,915,633 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 552,926 | $3,455,788 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 255,060 | $2,943,392 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 116,353 | $2,381,746 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 732,463 | $2,065,546 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 59,017 | $1,979,430 | dollars as filed | |
| INOZYME PHARMA INC | 45790W108 | COM | 499,254 | $454,321 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001964437-25-000005 | this filing | 2025-05-15 | acceptance time not in the bulk data set |